Toggle Main Menu Toggle Search

Open Access padlockePrints

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report

Lookup NU author(s): Dr Mustafa Sevinc, Dr Vicky Brocklebank, Professor Tim Goodship, Professor David KavanaghORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2015 Sevinc et al.; licensee BioMed Central.Introduction: Thrombotic microangiopathies are a group of diseases presenting as microangiopathic hemolytic anemia, thrombocytopenia and end-organ dysfunction. As the role of the complement system was elucidated in atypical hemolytic uremic syndrome pathogenesis, eculizumab was successfully introduced into clinical practice. We present a large pedigree with multiple individuals carrying a functionally significant novel factor H mutation. We describe the proband's presentation following a presumed infectious trigger requiring plasma exchange and hemodialysis. Case presentation: A 32-year-old Caucasian woman presented with pyrexia and headache lasting one week to our Emergency Department. She gave no history of diarrhea or other symptoms to account for her high temperature. She was not taking any medication. She was pyrexial (38°C), tachycardic (110bpm) and hypertensive (160/110mmHg). Her fundoscopy revealed grade IV hypertensive retinopathy. She had mild pretibial and periorbital edema, with oliguria (450mL/day). She had a pregnancy one year previously, during which she had hypertension, proteinuria and edema, with successful delivery at term. Her mother had died in her early 30s with a clinical picture consistent with thrombotic microangiopathy. Her laboratory evaluation showed microangiopathic hemolytic anemia. After 22 sessions of plasma exchange, her lactate dehydrogenase levels started to climb. As a result, she was classified as plasma resistant and eculizumab therapy was instituted. Her lactate dehydrogenase level and platelet count normalized, and her renal function recovered after three months of dialysis. Conclusions: We demonstrate that, even in patients with atypical hemolytic uremic syndrome and prolonged dialysis dependence, recovery of renal function can be seen with eculizumab treatment. We suggest a treatment regime of at least three months prior to evaluation of efficacy.

Publication metadata

Author(s): Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship THJ, Kavanagh D, Unsal A

Publication type: Article

Publication status: Published

Journal: Journal of Medical Case Reports

Year: 2015

Volume: 9

Online publication date: 29/04/2015

Acceptance date: 18/03/2015

Date deposited: 14/07/2017

ISSN (electronic): 1752-1947

Publisher: BioMed Central Ltd.


DOI: 10.1186/s13256-015-0575-y


Altmetrics provided by Altmetric